Detalhe da pesquisa
1.
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Blood
; 142(12): 1056-1070, 2023 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37339579
2.
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
Haematologica
; 108(6): 1500-1514, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226489
3.
The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases.
Res Sq
; 2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36865133
4.
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Blood Cancer J
; 13(1): 101, 2023 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37386016
5.
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
J Hematol Oncol
; 16(1): 73, 2023 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37422688
6.
In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals.
JCI Insight
; 7(7)2022 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35230977
7.
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.
Leukemia
; 37(6): 1379-1383, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37085610